SCHEMBL1093590

SCHEMBL1093590

NC(=O)c1ccc(Oc2cc(Cl)c(C(C3CCNC3=O)N3CCC(O)CC3)c(Cl)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 14/20 0.37
PARP14 Q460N5 6/20 0.37
PARP15 Q460N3 4/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
PARP16 Q8N5Y8 1/20 0.37
PARP11 Q9NR21 1/20 0.37
PARP4 Q9UKK3 1/20 0.37
F2 P00734 2/20 0.35
ST14 Q9Y5Y6 2/20 0.35
SCN9A Q15858 2/20 0.35
FPR2 P25090 1/20 0.35
PARP2 Q9UGN5 2/20 0.34
TNKS O95271 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
CHEK2 O96017 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
PRSS1 P07477 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1092690 0.86 HRH3 (0.39) PARP10PARP15SCN9APARP2
SCHEMBL1092032 0.86 CHEK2 (0.36) PARP10PARP14PARP15ALDH1A1KMT2A
SCHEMBL1092764 0.76
SCHEMBL2994149 0.73 ALDH1A1 (0.35) ALDH1A1KMT2AF2ST14PRSS1
SCHEMBL2065491 0.69 PDE4D (0.41) ALDH1A1OPRD1
SCHEMBL1093584 0.69 PARP10 (0.37) PARP10PARP14PARP15ALDH1A1KMT2A
SCHEMBL2065311 0.69 ALDH1A1 (0.40) ALDH1A1OPRD1
SCHEMBL1093587 0.69 PARP10 (0.37) PARP10PARP14PARP15ALDH1A1KMT2A
SCHEMBL1092157 0.67 PDE4D (0.32)
SCHEMBL4181004 0.65 PDE4D (0.39) ALDH1A1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153807-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-04-10 US disclosed
EP-2021336-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-30 EP disclosed
US-20090111809-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 BUSH JULIE KAY 2009-04-30 US disclosed
EP-2021336-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-02-11 EP disclosed
WO-2007127688-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111809-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD3B1, HSD11B2 PARP10 1200/4885PARP14 1845/4885PARP15 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.